Elise Lepeltier
Overview
Explore the profile of Elise Lepeltier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guerin M, Lepeltier E
Drug Deliv Transl Res
. 2024 Apr;
14(8):2276-2297.
PMID: 38587757
Over the past decades, research on nanomedicines as innovative tools in combating complex pathologies has increased tenfold, spanning fields from infectiology and ophthalmology to oncology. This process has further accelerated...
2.
Genedy H, Humbert P, Laoulaou B, Le Moal B, Fusellier M, Passirani C, et al.
Adv Drug Deliv Rev
. 2024 Feb;
207:115214.
PMID: 38395361
Low back pain stands as a pervasive global health concern, afflicting almost 80% of adults at some point in their lives with nearly 40% attributable to intervertebral disc degeneration (IVDD)....
3.
Toussaint F, Lepeltier E, Franconi F, Pautu V, Jerome C, Passirani C, et al.
Colloids Surf B Biointerfaces
. 2024 Feb;
235:113788.
PMID: 38335770
Surface modification of lipid nanocapsules (LNC) is necessary to impart stealth properties to these drug carriers and enhance their accumulation into the tumor microenvironment. While pegylation is commonly used to...
4.
Salmain M, Gaschard M, Baroud M, Lepeltier E, Jaouen G, Passirani C, et al.
Cancers (Basel)
. 2023 Sep;
15(18).
PMID: 37760418
Cancers classified as multidrug-resistant (MDR) are a family of diseases with poor prognosis despite access to increasingly sophisticated treatments. Several mechanisms explain these resistances involving both tumor cells and their...
5.
Idlas P, Lepeltier E, Bastiat G, Pigeon P, McGlinchey M, Lautram N, et al.
Langmuir
. 2023 Jan;
39(5):1885-1896.
PMID: 36693216
Ferrocifens, lipophilic organometallic complexes, comprise a biologically active redox motif [ferrocenyl-ene--phenol] which confers very interesting cytotoxic properties to this family. However, because of their highly lipophilic nature, a formulation stage...
6.
Baroud M, Lepeltier E, Thepot S, El-Makhour Y, Duval O
Nanoscale Adv
. 2022 Sep;
3(8):2157-2179.
PMID: 36133769
Nucleoside and nucleotide analogs are essential tools in our limited arsenal in the fight against cancer. However, these structures face severe drawbacks such as rapid plasma degradation or hydrophilicity, limiting...
7.
Idlas P, Ladaycia A, Nemati F, Lepeltier E, Pigeon P, Jaouen G, et al.
Int J Pharm
. 2022 Sep;
626:122164.
PMID: 36089209
Ovarian cancer is one of the deadliest epithelial malignancies in women, owing to the multidrug resistance that restricts the success of conventional chemotherapy, carboplatin and paclitaxel. High grade serous ovarian...
8.
Le Moal B, Lepeltier E, Rouleau D, Le Visage C, Benoit J, Passirani C, et al.
Int J Pharm
. 2022 Jul;
624:121941.
PMID: 35781028
Approximately 40% of cases of lower back pain are caused by disc degeneration disease (DDD). It is well established that microRNA (miR) dysregulation is a key player in various diseases,...
9.
Resnier P, Lepeltier E, Emina A, Galopin N, Bejaud J, David S, et al.
RSC Adv
. 2022 May;
9(47):27264-27278.
PMID: 35529231
Malignant melanoma is an aggressive tumor, associated with the presence of local and/or distant metastases. The development of gene therapy by the use of small interfering RNA (siRNA) represents a...
10.
Labrak Y, Heurtault B, Frisch B, Saulnier P, Lepeltier E, Miron V, et al.
Int J Pharm
. 2022 Mar;
618:121623.
PMID: 35231547
Impairment of oligodendrocyte progenitor cell (OPC) differentiation into oligodendrocytes and chronic inflammation are key determinants of poor remyelination observed in diseases such as multiple sclerosis. For many pro-myelinating molecules, the...